LaserOptek, a South Korean specialist in aesthetic and therapeutic laser devices, has launched VASCURA589, a high-power 589nm solid-state vascular laser. The device, unveiled at the VASCURA 589 PREMIERE event in Seoul on June 13, 2026, introduces proprietary KGW Raman laser technology that overcomes long-standing technical barriers in solid-state laser output at this wavelength. For overseas distributors and clinic buyers, this innovation signals a new option in vascular lesion treatment devices with lower maintenance requirements and stable performance.
Technology breakthrough
VASCURA589 is built on LaserOptek's proprietary KGW Raman laser technology, which uses Raman scattering to achieve high-power 589nm output from a solid-state laser — a world-first, according to the company. Solid-state lasers typically struggle to deliver clinically meaningful energy at this wavelength, but LaserOptek claims its technology resolves this challenge while retaining the structural advantages of solid-state lasers, such as low maintenance and stability. The technology has been published in the international journal Applied Sciences (MDPI) and related patents have been filed.
Clinical applications and features
The 589nm wavelength targets oxyhemoglobin in blood vessels, making it effective for treating vascular lesions including port-wine stains, hemangiomas, telangiectasia, rosacea, and facial redness. The device employs a quasi-long pulse mode that gradually accumulates heat in vascular lesions for safe, sustained energy delivery. It supports pulse widths from 0.5ms to 40ms, enabling precise control based on lesion size and depth. With a maximum repetition rate of 10Hz and multiple spot sizes, the system also includes a CSC cooling system to protect the epidermis during treatment and improve patient comfort.
Market signal
The launch strengthens LaserOptek's therapeutic laser portfolio and positions the company to compete in the global vascular skin disease treatment market. CEO Lee Chang-jin stated that VASCURA589 represents a "monumental product" that solves an industry-wide challenge using proprietary technology. The development was supported by the Ministry of SMEs and Startups' SME Innovation Development Project, indicating government backing for advanced medical device R&D in South Korea.
What buyers should watch
For overseas importers and clinic buyers, VASCURA589 offers a solid-state alternative to traditional pulsed dye lasers (PDL) for vascular treatments. Its lower maintenance requirements and stable output could reduce operational costs. The device's 589nm wavelength and adjustable parameters may appeal to clinics seeking to expand vascular treatment capabilities. However, buyers should evaluate clinical data presented at the launch event, including results shared by Dr. Oh Chang-geun of OZ Dermatology Clinic, and consider regulatory approvals in their target markets before procurement decisions.
Source: Read the original report | Published: June 15, 2026